Weekly Research Analysts’ Ratings Updates for CorMedix (CRMD)

CorMedix (NASDAQ: CRMD) recently received a number of ratings updates from brokerages and research firms:

• 1/12/2026 – CorMedix was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 1/8/2026 – CorMedix was given a new $16.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – CorMedix had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a “buy” rating on the stock.
• 1/8/2026 – CorMedix had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
• 12/18/2025 – CorMedix had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.

Insider Buying and Selling at CorMedix

In related news, CEO Joseph Todisco sold 30,000 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $12.00, for a total value of $360,000.00. Following the completion of the sale, the chief executive officer owned 509,496 shares in the company, valued at approximately $6,113,952. This represents a 5.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Myron Kaplan bought 25,000 shares of the firm’s stock in a transaction dated Thursday, October 23rd. The shares were bought at an average price of $11.02 per share, with a total value of $275,500.00. Following the completion of the transaction, the director directly owned 201,034 shares in the company, valued at approximately $2,215,394.68. This trade represents a 14.20% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders sold 90,000 shares of company stock valued at $1,095,200. 3.10% of the stock is currently owned by corporate insiders.

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.